echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: The safety of upatinib in the treatment of rheumatoid arthritis

    Ann Rheum Dis: The safety of upatinib in the treatment of rheumatoid arthritis

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Upatinib is a Janus kinase inhibitor.


    Upatinib is a Janus kinase inhibitor.


     

    The study pooled treatment emergency adverse events (TEAEs) and laboratory data from five phase III trials.


    The study pooled treatment emergency adverse events (TEAEs) and laboratory data from five phase III trials.


    3834 patients received upatinib treatment, of which 15 mg (n = 2630) and 30 mg (n = 1204).


    3834 patients received upatinib treatment, of which 15 mg (n = 2630) and 30 mg (n = 1204).


     

    Compared with adalimumab, patients with upatinib have an increased risk of herpes zoster and CPK.


    Compared with adalimumab, patients with upatinib have an increased risk of herpes zoster and CPK.


     

    Original source:

    Original source: Original source:

    Stanley B Cohen.


    Stanley B Cohen.
    bmj.
    com/content/80/3/304" target="_blank" rel="noopener">Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Ann Rheum Dis.
    February 2021.
    bmj.
    com/content/80/3/304" target="_blank" rel="noopener">Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.